IL164734A0 - Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof - Google Patents

Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Info

Publication number
IL164734A0
IL164734A0 IL16473404A IL16473404A IL164734A0 IL 164734 A0 IL164734 A0 IL 164734A0 IL 16473404 A IL16473404 A IL 16473404A IL 16473404 A IL16473404 A IL 16473404A IL 164734 A0 IL164734 A0 IL 164734A0
Authority
IL
Israel
Prior art keywords
derivatives
carboxylic acids
sub
site
action
Prior art date
Application number
IL16473404A
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IL164734A0 publication Critical patent/IL164734A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
IL16473404A 2002-05-14 2004-10-20 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof IL164734A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38064102P 2002-05-14 2002-05-14

Publications (1)

Publication Number Publication Date
IL164734A0 true IL164734A0 (en) 2005-12-18

Family

ID=29549994

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16473404A IL164734A0 (en) 2002-05-14 2004-10-20 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Country Status (16)

Country Link
US (2) US7355047B2 (enExample)
EP (1) EP1503759B1 (enExample)
JP (1) JP4532263B2 (enExample)
KR (1) KR20040107525A (enExample)
CN (1) CN1652784A (enExample)
AT (1) ATE417613T1 (enExample)
AU (1) AU2003229043B2 (enExample)
BR (1) BR0309965A (enExample)
CA (1) CA2484308A1 (enExample)
DE (1) DE60325347D1 (enExample)
DK (1) DK1503759T3 (enExample)
ES (1) ES2319176T3 (enExample)
IL (1) IL164734A0 (enExample)
MX (1) MXPA04011156A (enExample)
NZ (1) NZ536061A (enExample)
WO (1) WO2003097564A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0309965A (pt) * 2002-05-14 2005-03-01 Univ California ácidos carboxìlicos com quinolona substituìda, seus derivados, local de ação, e usos dos mesmos
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
RU2006142896A (ru) * 2004-05-06 2008-06-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния (Us) Замещенные енаминоны, их производные и их применение
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
WO2006002421A2 (en) * 2004-06-24 2006-01-05 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
CA2605384A1 (en) * 2005-04-11 2006-10-19 F. Hoffman-La Roche Ag (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines
BRPI0611537A2 (pt) * 2005-05-04 2010-09-21 Hoffmann La Roche (3,4-diidro-quinazolin-2-il) -(2-arilóxi-etil)-aminas tendo uma atividade sobre o receptor de 5-ht
AU2006322045A1 (en) * 2005-12-05 2007-06-14 Merck & Co., Inc. Quinolone M1 receptor positive allosteric modulators
US20090105272A1 (en) * 2005-12-24 2009-04-23 Grootenhuis Peter D J Prodrugs of modulators of ABC transporters
AU2006332726B2 (en) * 2005-12-28 2012-12-13 Vertex Pharmaceuticals Incorporated. Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2383271B1 (en) * 2006-03-13 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Aminoquinolones as GSK-3 Inhibitors
WO2008017710A1 (en) * 2006-08-10 2008-02-14 Ferrer Internacional S.A. 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions
EP1886996A1 (en) * 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
WO2008046135A1 (en) 2006-10-16 2008-04-24 Bionomics Limited Novel anxiolytic compounds
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
WO2009040377A2 (en) * 2007-09-27 2009-04-02 Ge Healthcare Limited Imaging agents
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CA2741126A1 (en) * 2008-10-23 2010-04-29 Merck Sharp & Dohme Corp. Fused heterocyclic m1 receptor positive allosteric modulators
AU2010226400B2 (en) 2009-03-20 2016-07-14 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US20120093917A1 (en) * 2009-04-02 2012-04-19 Robert Hromas Metnase and intnase inhibitors and their use in treating cancer
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US20140051701A1 (en) * 2011-03-02 2014-02-20 Bionomics Limited Methods of treating a disease or condition of the central nervous system
US9023848B2 (en) 2011-03-02 2015-05-05 Bionomics Limited Small-molecules as therapeutics
AU2012253237B2 (en) 2011-05-12 2015-09-24 Bionomics Limited Methods for preparing naphthyridines
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
CN107501107A (zh) * 2017-09-26 2017-12-22 兰亚朝 喹诺酮药物的中间体合成方法
CN111269131B (zh) * 2020-03-12 2021-12-28 江苏飞宇医药科技股份有限公司 以三正丙胺为吸酸剂制备环丙乙酯胺化物的工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
JPS5715760B2 (enExample) * 1974-06-11 1982-04-01
US4390541A (en) 1980-12-19 1983-06-28 Lilly Industries Limited Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
JP2002544197A (ja) * 1999-05-06 2002-12-24 ニューロゲン コーポレイション 置換４−オキソ−キノリン−３−カルボキサミド：ｇａｂａ脳受容体リガンド
GB0127349D0 (en) * 2001-11-14 2002-01-02 Glaxo Group Ltd Macrolides
BR0309965A (pt) * 2002-05-14 2005-03-01 Univ California ácidos carboxìlicos com quinolona substituìda, seus derivados, local de ação, e usos dos mesmos

Also Published As

Publication number Publication date
WO2003097564A3 (en) 2004-02-26
MXPA04011156A (es) 2005-02-17
EP1503759A2 (en) 2005-02-09
DE60325347D1 (de) 2009-01-29
ES2319176T3 (es) 2009-05-05
KR20040107525A (ko) 2004-12-20
AU2003229043A1 (en) 2003-12-02
CN1652784A (zh) 2005-08-10
AU2003229043B2 (en) 2008-12-04
US20060178516A1 (en) 2006-08-10
ATE417613T1 (de) 2009-01-15
US20080176897A1 (en) 2008-07-24
BR0309965A (pt) 2005-03-01
CA2484308A1 (en) 2003-11-27
JP4532263B2 (ja) 2010-08-25
WO2003097564A2 (en) 2003-11-27
JP2005535592A (ja) 2005-11-24
US7355047B2 (en) 2008-04-08
NZ536061A (en) 2008-09-26
EP1503759A4 (en) 2006-02-15
DK1503759T3 (da) 2009-04-14
HK1072905A1 (en) 2005-09-16
EP1503759B1 (en) 2008-12-17

Similar Documents

Publication Publication Date Title
IL164734A0 (en) Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
WO2000045799A3 (de) Verwendung von substituierten isoxazolcarbonsäuren und derivaten und neue stoffe
ATE370943T1 (de) Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
IL162527A0 (en) Novel fluorene carboxylic acid esters, methods forthe production thereof, and use of the same as pharmaceuticals
NO20072767L (no) Gabapentin prodrug vedvarende frigivelse orale doseringsformer
IL158923A0 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
AP2005003418A0 (en) Alpha substituted carboxylic acids as ppar modulators.
NO20034920D0 (no) Styrking av terapeutiske virkninger av fettsyrer
AU2003293311A8 (en) Secondary binding site of dipeptidyl peptidase iv (dp iv)
IS7497A (is) (1a,3a,5a)(3-amínómetýl bísýkló[3.2.0]hept-3-ýl)l-ediksýra, lyfjasamsetningar og notkun efnasambands til framleiðslu á lyfjum
DK1706457T3 (da) Fremstilling af 3-hydroxypropionsyre ved anvendelse af beta-alanin/pyruvataminotransferase
PT1140945E (pt) Derivados 1 2 4 tiadiazina fundidos a sua preparacao e a sua utilizacao
WO2003032912A3 (en) Treatment of cns disorders using cns target modulators
DK0946176T3 (da) Anvendelse af 7-(2-oxa-5,8-diazabicyclo[4.3.0]quinoloncarboxylsyre- og naphthydridoncarboxylsyrederivater til fremstilling af et lægemiddel til behandling af Helicobacter-pylori-infektioner og dermed associerede gastroduodenale sygdomme
UA85711C2 (ru) Замещенные енаминоны, их производные и их применение
NO20044868L (no) Fremgangsmater for behandling av gastrointestinal og genitourinsmerte forstyrrelser ved bruk av vinlafaxin og derivater
WO2006123200A3 (en) Multiple source/multiple device connector
AU2003304226A1 (en) Inhibition of rosin crystallization
AU6689900A (en) 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors
BG104801A (en) Indole-2,3-dione-3-oxime derivatives for therapeutical use
AU2001247233A1 (en) Ppar gamma agonists for the treatment of liver inflammatory disorders
DE602004003173D1 (de) Verwendung von konjugierter Linolsäure zur Behandlung der Erkältung
WO2003045917A3 (en) Ccr-3 receptor antagonists vii
MXPA03002047A (es) Fenilciclohexanocarboxamidas substituidas y su uso.
NO20014059L (no) Krystallmodifikasjon D av 8-cyano-1-cyklopropyl-7-(1S,6S-2,8- diazabicyklo-/4.3.0/-nonan-8-yl)-6-fluor-1,4-dihydro-4-okso-3-kinolinkarboksylsyre